Hotline Update of Clinical Trials and Registries presented at the German Cardiac Society Meeting 2007: 2L-Registry, Kardio-Pro, EVER, AFFECT, VTACH, ARTS II, OPTAMI, PEPCAD I, PEPCAD II, GERSHWIN, SPICE, FIX-CHF and CREDI

Clinical Research in Cardiology

Volumn 96, Issue 7, 2007, Pages 457-468

  Rosenkranz, Stephan ^a   Maier, Lars S ^b   Maack, Christoph ^c   Böhm, Michael ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

2L Registry; AFFECT; ARTS II; CREDIT; EVER; FIX CHF; GERSHWIN; Kardio Pro; OPTAMI; PEPCAD I; PEPCAD II; SPICE; VTACH

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERTOPARIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; PHENPROCOUMON; RAPAMYCIN; WARFARIN;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ARTERY DISEASE; BLEEDING; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTRAST RADIOGRAPHY; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG ELUTING STENT; GERMANY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; MEDICAL SOCIETY; MORBIDITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROCESS OPTIMIZATION; PROSPECTIVE STUDY; REVIEW; SECONDARY PREVENTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT INDICATION;

CARDIOLOGY; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; GERMANY; HOTLINES; HUMANS; META-ANALYSIS AS TOPIC; REGISTRIES; SOCIETIES, MEDICAL;

EID: 34347325042     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-007-0548-2     Document Type: Review

References (22)

1. Gohlke H, Kübler W, Mathes P, Meinertz T, Schuler G, Gysan DB, Sauer G (2001) Recommendations for an extensive risk decrease for patients with coronary disease, vascular diseases and diabetes. Issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research, reviewed on behalf of the Clinical Cardiology Commission by the Prevention Project Group. Z Kardiol 90:148-149
2. Bjarnason-Wehrens B, Bott D, Benesch L, Bischoff KO, Buran-Kilian B, Gysan D, Hollenstein U, Mayer-Berger W, Wilkniss R, Sauer G (2007) Long-term results of a three-week intensive cardiac out-patient rehabilitation program in motivated patients with low social status. Clin Res Cardiol 96:77-85
3. Bischoff B, Silber S, Richartz BM, Pieper L, Klotsche J, Wittchen HU (2006) Inadequate medical treatment of patients with coronary artery disease by primary care physicians in Germany. Clin Res Cardiol 95:405-412
4. Lip GY, Hart RG, Conway DS (2002) Antithrombotic therapy for atrial fibrillation. BMJ 325:1022-1025
5. Foulkes MA, Wolf PA, Price TR, Mohr JP, Hier DB (1988) The stroke databank (NINDS): Design, methods, and baseline characteristics. Stroke 19:547-554
6. Klein AL, Murray RD, Grimm RA, Li J, Apperson-Hansen C, Jasper SE, Goodman-Bizon AS, Lieber EA, Black IW, for the ACUTE Investigators (2003) Bleeding complications in patients with atrial fibrillation undergoing cardioversion randomized to transoesophageal echocardiography guided and conventional anticoagulation therapies (ACUTE trial). Am J Cardiol 92:161-165
7. Klein AL, Grimm RA, Jasper SE, Murray RD, Apperson-Hansen C, Lieber EA, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF, ACUTE Investigators (2006) Efficacy of transesophageal echocardiography- guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial. Am Heart J 151:380-389
8. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mügge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke A, for the ACE Study Group (2004) Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 109:997-1003
9. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schonberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, van Hout BA (2001) Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344:1117-1124
10. Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, Nielsen TT, Paulsen PK, Gomes RS, de Queiroz e Melo JM, Neves JP, Lindeboom W, Backx B (2004) Threeyear outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. Circulation 109:1114-1120
11. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, Schonberger JP, Buller N, Bonser R, Disco C, Backx B, Hugenholtz PG, Firth BG, Unger F (2005) Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 46:575-581
12. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U (2006) Treatment of coronary in-stent restenosis with a paclitaxel- coated balloon catheter. N Engl J Med 355:2113-2124
13. Scheller B (2006) Treatment of in- Stent restenosis by a paclitaxel coated balloon catheter - PACCOCATH ISR II Trial. Presented at the Scientific Hot Line Sessions of the American Heart Association (AHA), November 13 2006, Chicago, USA
14. Tepe et al (2006) Transcatheter Cardiovascular Therapeutics (TCT), October 23 2006
15. Schwinger RH, Pietsch M, Frank K, Brixius K (2000) Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol 35:700-707
16. Holubarsch CJ, Colucci WS, Meinertz T, Gaus W, Tendera M (2000) Survival and prognosis: investigation of Crataegus extract WS 1442 in congestive heart failure (SPICE)-rationale, study design and study protocol. Eur J Heart Fail 2:431-437
17. Ammar KA, Jacobsen SJ, Mahoney DW, Kors JA, Redfield MM, Burnett JC Jr, Rodehelfer RJ (2007) Prevalence and prognostic significance of heart failure stages: Application of the American College of Cardiology/ merican Heart Association heart failure staging criteria in the community. Circulation 115:1563-1570
18. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, Cardiac Resynchronization- Heart Failure (Care-HF) Study Investigators (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539-1549
19. Sabbah HN, Haddad W, Mika Y, Nass O, Aviv R, Sharov VG, Maltsev V, Felzen B, Undrovinas AI, Goldstein S, Darvish N, Ben-Haim SA (2001) Cardiac contractility modulation with the impulse dynamics signal: studies in dogs with chronic heart failure. Heart Fail Rev 6:45-53
20. Cazeau S, Leclerq C, Lavergne T, Walker S, Varma C, Linde C, Garrique S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC, Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators (2001) Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344:837-880
21. Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105:310-315. Erratum in: Circulation (2002) 105:900
22. Vester EG, Stellbrink C, de Haan F, Treusch S (2007) Kardiale Resynchronisation und ICD-Implantation - das CRediT-Register zur aktuellen Versorgungslage in Deutschland